Immune Profiling of Adenoid Cystic Carcinoma: PD-L2 Expression and Associations with Tumor-Infiltrating Lymphocytes
Vishwajith Sridharan(Massachusetts General Hospital), Jonathan D. Schoenfeld(Brigham and Women's Hospital), Glenn Dranoff(Dana-Farber Cancer Institute), Scott J. Rodig(Brigham and Women's Hospital), Mariano Severgnini(Dana-Farber Cancer Institute), Gordon J. Freeman(Dana-Farber Cancer Institute), Adel K. El‐Naggar(Barking, Havering And Redbridge University Hospitals NHS Trust), Xiaoyun Liao(Dana-Farber Cancer Institute), Robert I. Haddad(Georgetown University), F. Stephen Hodi(Harvard University), Peter S. Hammerman(Broad Institute), Nicole G. Chau(University of British Columbia), Evisa Gjini(Brigham and Women's Hospital)
Cited by 101
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
|Journal of Clinical Oncology|2014|2.2k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k